Doxepin (Mareen)
A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
Also Known As:
Mareen; Zonalon; Aponal; Sinequan; Sinquan; Aliud Brand of Doxepin Hydrochloride; Alphapharm Brand of Doxepin Hydrochloride; Apo-Doxepin; Apotex Brand of Doxepin Hydrochloride; Azupharma Brand of Doxepin Hydrochloride; Bioglan Brand of Doxepin Hydrochloride; Deptran; Desidox; Desitin Brand of Doxepin Hydrochloride; Doneurin; Doxepia; Doxepin AL; Doxepin AZU; Doxepin Holsten; Doxepin Hydrochloride; Doxepin Hydrochloride, Cis-Trans Isomer Mixture (approximately 1:5); Doxepin Lindo; Doxepin Stada; Doxepin beta; Doxepin dura; Doxepin-RPh; Doxepin-TEVA; Doxepin-neuraxpharm; Doxepin-ratiopharm; Espadox; Healthpoint Brand of Doxepin Hydrochloride; Hexal Brand of Doxepin Hydrochloride; Holsten Brand of Doxepin Hydrochloride; Krewel Brand of Doxepin Hydrochloride; Lindopharm Brand of Doxepin Hydrochloride; Merck dura Brand of Doxepin Hydrochloride; Nepalm Brand of Doxepin Hydrochloride; Novo-Doxepin; Novopharm Brand of Doxepin Hydrochloride; Pfizer Brand of Doxepin Hydrochloride; Prudoxin; Quitaxon; Roche Brand of Doxepin Hydrochloride; Rodleben Brand of Doxepin Hydrochloride; Stadapharm Brand of Doxepin Hydrochloride; Temmler Brand of Doxepin Hydrochloride; Teva Brand of Doxepin Hydrochloride; Xepin; betapharm Brand of Doxepin Hydrochloride; biomo Brand of Doxepin Hydrochloride; doxepin-biomo; esparma Brand of Doxepin Hydrochloride; neuraxpharm Brand of Doxepin Hydrochloride; ratiopharm Brand of Doxepin Hydrochloride; Apo Doxepin; ApoDoxepin; Doxepin RPh; Doxepin TEVA; Doxepin neuraxpharm; Doxepin ratiopharm; Hydrochloride, Doxepin; Lindo, Doxepin; Novo Doxepin; Stada, Doxepin; doxepin biomo; doxepinbiomo; 1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N-dimethyl-
Networked: 269
relevant articles (35 outcomes,
59 trials/studies)
Relationship Network
Drug Context: Research Results
Experts
1. | Rogowski, Roberta:
7 articles
(02/2012 - 11/2007)
|
2. | Roth, Thomas:
6 articles
(02/2012 - 11/2007)
|
3. | Lankford, Alan:
5 articles
(02/2012 - 11/2007)
|
4. | Ludington, Elizabeth:
5 articles
(02/2012 - 10/2010)
|
5. | Jochelson, Philip:
4 articles
(10/2011 - 10/2010)
|
6. | Oien, Hal:
4 articles
(03/2008 - 01/2003)
|
7. | Epstein, Joel B:
4 articles
(03/2008 - 01/2003)
|
8. | Truelove, Edmond L:
4 articles
(03/2008 - 01/2003)
|
9. | Przewlocka, B:
3 articles
(05/2015 - 10/2005)
|
10. | Mika, Joanna:
3 articles
(02/2015 - 01/2013)
|
Related Diseases
1. | Sleep Initiation and Maintenance Disorders (Insomnia)
01/01/2012
- " Low-dose doxepin may have a unique role in the treatment of insomnia in elderly patients given its tolerability, documented efficacy, and lack of important adverse effects." 08/01/2010
- " Oral, low-dose doxepin 6 mg was also significantly more effective than placebo in a large, well designed trial modelling transient insomnia in healthy adults, according to polysomnographic recordings (e.g. " 08/01/2010
- " In three large, well designed, phase III trials in adult or elderly patients with chronic primary insomnia, oral, low-dose doxepin 3 or 6 mg once daily improved wake time after sleep onset, total sleep time and sleep efficiency to a significantly greater extent than placebo. " 10/01/2008
- " In this 2-night study of elderly adults with primary insomnia, doxepin doses of 1 mg, 3 mg, and 6 mg were well tolerated and produced significant improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night. " 07/01/2013
- " Compared to placebo, doxepin improved the Insomnia Severity Index (-9 ± 5.4 vs. -2 ± 3.9, p = 0.03), the SCOPA-night score (-5.2 ± 1.5 vs. -2.3 ± 2.8, p = 0.049), the Pittsburgh Sleep Quality Index-sleep disturbances subscale (-0.5 ± 0.5 vs 0.2 ± 0.4, p = 0.02), and both patient and examiner-rated clinical global impression of change (1.7 ± 0.8 vs. 0.5 ± 0.8, p = 0.03 and 1.4 ± 0.5 vs. 0.3 ± 0.5, p = 0.003). "
|
2. | Pruritus (Itching)
|
3. | Pain (Aches)
|
4. | Neuralgia (Stump Neuralgia)
|
5. | Atopic Dermatitis (Atopic Eczema)
|
|
Related Drugs and Biologics
Related Therapies and Procedures